We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
19.00 | 1.07% | 1,799.50 | 1,796.00 | 1,796.50 | 1,799.50 | 1,780.00 | 1,784.00 | 9,804,173 | 16:35:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 15.00 | 73.94B |
Date | Subject | Author | Discuss |
---|---|---|---|
25/1/2018 11:24 | Buy @£12.99 | abdullla | |
24/1/2018 14:29 | Yes I pay for L2 you see the trades. | montyhedge | |
24/1/2018 14:08 | Thanks MH, ah ok I think that function/visibility is behind their paywall, which I can't access. The trades list view times out so quickly you just get a glimpse of what you can't access. A shame as if it were free I'd find it useful... | jrphoenixw2 | |
24/1/2018 13:54 | speedsgh, I bet they were short prior to the article, markets full of crooks trying to pinch our cash ;) Alphorn, New Placing but only to the privileged few ! | gbh2 | |
24/1/2018 13:48 | If Investors Chronicle is out it is certainly time to pile in, their "advice" is even worse than the Motley Fool adverts. | romeike | |
24/1/2018 13:43 | >>speedsgh What a silly article if it follows in the vein of the opening paragraph. Why wait for the dividend? why not sell now or even better why didn't the author sell yesterday? The author has been with the company 18 years. He may have added or sold during that time but 18 years ago the share price was over £15 so s/he the author is just realising the loss on those shares bought 18 months ago. He considers that the stock is in play now which may be right as the company is trading at a round a 7 year low and 7 years ago the stock was rising whereas now it appears to be on the cusp. (either up on good or reasonable results - or down if results or poor) If results are poor then it really will be in play. Last quarters results were promising, let me remind you what the CE said, " Performance in the quarter showed continued progress with sales growth and improved operating margin. This was driven by targeted cost savings and restructuring and integration benefits, which particularly benefited Vaccines and Consumer Healthcare, and also supported investment in our new products and R&D pipeline. Adjusted earnings per share for Q3 were 32.5p and we remain on course for our full-year earnings guidance, with cash generation continuing to improve. We are also pleased that we have secured major approvals for Trelegy Ellipta in COPD and Shingrix, our shingles vaccine.” Reminds me not to get the Investors Chronicle. | darias | |
24/1/2018 13:24 | jr On Advfn trade deals went through the time I posted. | montyhedge | |
24/1/2018 13:18 | Thats what I like about the market bull and bears. I go with this one 4 days ago, even if broken up worth 2050p a share. | montyhedge | |
24/1/2018 13:17 | @Monty Where are you looking to see that trade data? I usually just keep a weather-eye on Google/Finance. Largest 2-minute candle I see was 190k at c1364.80 at 8.02am. Volume/30-day avg right now is 2.73/8.12M at circa 1.14pm. That's low, an hour after 'half-time' and the vol is only 67% of average 1/2 day volume... zzzz! | jrphoenixw2 | |
24/1/2018 13:10 | FWIW Mr Bearbull column (Investors Chronicle) today signals that he is calling time on his near 18yr investment in GSK once it goes XD for the final payment... Time’s up for Glaxo - | speedsgh | |
24/1/2018 12:56 | Thx. Don't follow it. edit: They can not have opened the study data otherwise there must be a risk of insider trading??? Very close timing. "key data still on track to be announced before the end of Q1 2018". Thick Chinese walls. | alphorn | |
24/1/2018 12:55 | >>Monty Credit where its due Monty the MMs certainly played that one well. | darias | |
24/1/2018 12:54 | Alphorn They had a placing at 144p. These small bio companies, always seem to be raising money. | montyhedge | |
24/1/2018 12:50 | gbh - 11% down. Someone read my questions. ;) (Probably just profit taking)? | alphorn | |
24/1/2018 12:44 | WOW that some punt, did you see the 600,000 trade at 1358p. | montyhedge | |
24/1/2018 12:42 | Fall seems overdone, Dow looking good for 2.30pm open, GSK should go better later today. | montyhedge | |
24/1/2018 11:33 | I must admit boys, I think this is the most on investors minds, this possible Pfizer consumer bid, although CEO she said won't overpay if they did bid. Could this possibly be holding back the shareprice. | montyhedge | |
24/1/2018 11:30 | Over the last year the Dow gained more than 5000 points,is it likely to crash now? | abdullla | |
24/1/2018 10:58 | When the FTSE 100 falls, the good, bad and ugly get hit. | montyhedge | |
24/1/2018 10:37 | Moving with the market, 1% sod all on a share of this price imo. IMM showing its colours this morning Alp :)) | gbh2 | |
24/1/2018 08:40 | Its just fluctuations - serious future profits will fuel a banquet. "Look at market fluctuations as your friend rather than your enemy; profit from folly rather than participate in it." ~ Warren Buffett | tradermichael | |
24/1/2018 08:32 | Profit taking, no one went hungry taking a profit, lol. | montyhedge | |
24/1/2018 07:16 | Good results from Novartis this morning. | alphorn | |
23/1/2018 14:48 | Good point jrphoenixw2, always a good idea to compare performance to the wider ftse and to its peers, GSK doing well today - an interesting divergence in direction between GSK/AZN/SHP and the wider market at around 14:15, hopefully this sort of thing might develop as an ongoing trend this year as punters take profits in overvalued stocks elsewhere and move back to quality in healthcare. | romeike |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions